PDF(Pubmed)
Abstract：
The renin-angiotensin system (RAS) is known to affect diverse physiological processes that affect the functioning of many key organs. Angiotensin-converting enzyme (ACE) modulates a variety of bioactive peptides associated with pain. ACE inhibitors (ACEis) have found applications in the treatment of cardiovascular, kidney, neurological and metabolic disorders. However, ACEis also tend to display undesirable effects, resulting in increased pain sensitization and mechanical allodynia. In this review, we provide comprehensive discussion of preclinical and clinical studies involving the evaluation of various clinically approved ACEis. With the emerging knowledge of additional factors involved in RAS signaling and the indistinct pharmacological role of ACE substrates in pain, extensive studies are still required to elucidate the mechanistic role of ACE in pain perception.
摘要：
已知肾素-血管紧张素系统（RAS）会影响多种生理过程，从而影响许多关键器官的功能。血管紧张素转换酶(ACE)调节多种与疼痛相关的生物活性肽。ACE抑制剂（ACEis）已在心血管疾病的治疗中找到应用，肾,神经和代谢紊乱。然而,ACEis也倾向于显示不良效果，导致疼痛敏化和机械性异常性疼痛增加。在这次审查中,我们全面讨论了临床前和临床研究,涉及各种临床批准的ACEis的评估.随着对RAS信号传导中涉及的其他因素的认识和ACE底物在疼痛中的不明确的药理学作用，仍然需要广泛的研究来阐明ACE在疼痛感知中的机制作用。
